# Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

> **NCT03175367** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 272 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Evinacumab
- **DRUG:** Matching placebo
- **OTHER:** Background Lipid Modifying Therapy (LMT)

## Key facts

- **NCT ID:** NCT03175367
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-10
- **Primary completion:** 2020-05-22
- **Final completion:** 2020-12-14
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03175367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03175367, "Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03175367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*